81 related articles for article (PubMed ID: 10912929)
1. Increased cellularity of tumor-encased native vessels in prostate carcinoma is a marker for tumor progression.
Garcia FU; Taylor CA; Hou JS; Rukstalis DB; Stearns ME
Mod Pathol; 2000 Jul; 13(7):717-22. PubMed ID: 10912929
[TBL] [Abstract][Full Text] [Related]
2. Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer.
Gravdal K; Halvorsen OJ; Haukaas SA; Akslen LA
Cancer Res; 2009 Jun; 69(11):4708-15. PubMed ID: 19487287
[TBL] [Abstract][Full Text] [Related]
3. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB
J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301
[TBL] [Abstract][Full Text] [Related]
4. High-grade foamy gland prostatic adenocarcinoma on biopsy or transurethral resection: a morphologic study of 55 cases.
Zhao J; Epstein JI
Am J Surg Pathol; 2009 Apr; 33(4):583-90. PubMed ID: 19033862
[TBL] [Abstract][Full Text] [Related]
5. Computerized whole slide quantification shows increased microvascular density in pT2 prostate cancer as compared to normal prostate tissue.
van Niekerk CG; van der Laak JA; Börger ME; Huisman HJ; Witjes JA; Barentsz JO; Hulsbergen-van de Kaa CA
Prostate; 2009 Jan; 69(1):62-9. PubMed ID: 18780292
[TBL] [Abstract][Full Text] [Related]
6. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
[TBL] [Abstract][Full Text] [Related]
7. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
8. Independent association of angiogenesis index with outcome in prostate cancer.
Mehta R; Kyshtoobayeva A; Kurosaki T; Small EJ; Kim H; Stroup R; McLaren CE; Li KT; Fruehauf JP
Clin Cancer Res; 2001 Jan; 7(1):81-8. PubMed ID: 11205922
[TBL] [Abstract][Full Text] [Related]
9. The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy.
Cheng L; Koch MO; Juliar BE; Daggy JK; Foster RS; Bihrle R; Gardner TA
J Clin Oncol; 2005 May; 23(13):2911-7. PubMed ID: 15860849
[TBL] [Abstract][Full Text] [Related]
10. Morphologic features of prostate cancer-encased native vessels: An image analysis study.
Fernandez Gonzalez De La Vega C; Duenweg S; Jain P; Rubenstein SI; Bobholz S; Barrett MJ; LaViolette PS; Iczkowski KA
Pathol Res Pract; 2024 Apr; 256():155239. PubMed ID: 38461692
[TBL] [Abstract][Full Text] [Related]
11. Predictors of Gleason pattern 4/5 prostate cancer on prostatectomy specimens: can high grade tumor be predicted preoperatively?
Rubin MA; Mucci NR; Manley S; Sanda M; Cushenberry E; Strawderman M; Montie JE; Bassily NH
J Urol; 2001 Jan; 165(1):114-8. PubMed ID: 11125378
[TBL] [Abstract][Full Text] [Related]
12. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.
Cheng L; Poulos CK; Pan CX; Jones TD; Daggy JK; Eble JN; Koch MO
J Urol; 2005 Sep; 174(3):898-902. PubMed ID: 16093983
[TBL] [Abstract][Full Text] [Related]
13. Tertiary Gleason pattern 5 is a powerful predictor of biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma.
Hattab EM; Koch MO; Eble JN; Lin H; Cheng L
J Urol; 2006 May; 175(5):1695-9; discussion 1699. PubMed ID: 16600733
[TBL] [Abstract][Full Text] [Related]
14. Tumor neoangiogenesis in rebiopsied patients with prostatic carcinoma.
Volavsek M; Masera A; Ovcak Z
Acta Med Croatica; 1999; 53(2):73-8. PubMed ID: 10705624
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate.
Arora R; Koch MO; Eble JN; Ulbright TM; Li L; Cheng L
Cancer; 2004 Jun; 100(11):2362-6. PubMed ID: 15160339
[TBL] [Abstract][Full Text] [Related]
16. Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: correlation with grade and expression in high-grade prostatic intraepithelial neoplasia.
Jack GS; Brash AR; Olson SJ; Manning S; Coffey CS; Smith JA; Shappell SB
Hum Pathol; 2000 Sep; 31(9):1146-54. PubMed ID: 11014584
[TBL] [Abstract][Full Text] [Related]
17. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
[TBL] [Abstract][Full Text] [Related]
19. Telomerase reverse transcriptase subunit immunoreactivity: a marker for high-grade prostate carcinoma.
Iczkowski KA; Pantazis CG; McGregor DH; Wu Y; Tawfik OW
Cancer; 2002 Dec; 95(12):2487-93. PubMed ID: 12467061
[TBL] [Abstract][Full Text] [Related]
20. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
